Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00836667 | Sertraline Hydrochloride 100 mg Tablets, Fed | PHASE1 | COMPLETED | 18 | — | — | Mar 1, 2002 | Apr 1, 2002 | Aug 19, 2024 | 1 | Canada |
| NCT00836849 | Sertraline Hydrochloride 100 mg Tablets, Fasting | PHASE1 | COMPLETED | 24 | — | — | Mar 1, 2002 | Apr 1, 2002 | Aug 19, 2024 | 1 | Canada |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Zoloft® 100 mg Tablets | DRUG | 1 x 100 mg, single-dose fed |
| Sertraline hydrochloride 100 mg Tablets | DRUG | 1 x 100 mg, single-dose fed |
Inclusion Criteria: * Subjects will be females and/or males, non-smokers, 18 years of age and older. Female subjects will be post-menopausal or surgically sterilized. * Post-menopausal status is defined as absence of menses for the past 12 months. * Sterile status is defined as hysterectomy, bilate...